300 related articles for article (PubMed ID: 18382135)
1. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
2. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
3. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
5. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.
Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD
J Immunol; 2003 Nov; 171(10):5611-23. PubMed ID: 14607970
[TBL] [Abstract][Full Text] [Related]
6. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
7. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
8. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
10. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
Front Immunol; 2018; 9():2968. PubMed ID: 30631324
[TBL] [Abstract][Full Text] [Related]
11. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice.
Dakappagari NK; Sundaram R; Rawale S; Liner A; Galloway DR; Kaumaya PT
J Pept Res; 2005 Feb; 65(2):189-99. PubMed ID: 15705163
[TBL] [Abstract][Full Text] [Related]
12. Protective CD8
Ma Y; Tang K; Zhang Y; Zhang C; Cheng L; Zhang F; Zhuang R; Jin B; Zhang Y
Virol J; 2020 Oct; 17(1):146. PubMed ID: 33028368
[TBL] [Abstract][Full Text] [Related]
13. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
14. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
15. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
16. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
18. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
Lekka E; Gritzapis AD; Perez SA; Tsavaris N; Missitzis I; Mamalaki A; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2010 May; 59(5):715-27. PubMed ID: 19904532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
